At the Seventy-ninth World Health Assembly in May 2026, countries delivered sobering news wrapped in a message of resolve: immunization programmes are slipping in too many places, outbreaks of vaccine-preventable diseases are spreading, and inequities are widening. Yet in the same breath, they reaffirmed their commitment to Immunization Agenda 2030—and offered fresh proof that vaccines, when scaled, can reshape child survival in real time.

The stakes of this moment became concrete through the malaria vaccine rollout across Africa. Over four years, the RTS,S malaria vaccine averted roughly one in eight child deaths among eligible children in Ghana, Kenya, and Malawi—a staggering human impact that is now multiplying as 25 African countries have begun offering the vaccine. This is not projection or promise; this is documented prevention. The Director of the Department of Immunization, Vaccines and Biologicals at WHO called it "what integrated, life-course immunization looks like in practice"—a vaccine that not only prevents malaria but creates additional health care touchpoints to deliver other essential services that keep children alive.

Yet progress remains fragile because the world faces converging headwinds. Routine immunization coverage is slipping in too many countries. Misinformation is striking communities where trust has eroded. Conflict, climate pressures, and constrained financing are real barriers, not abstract ones. Outbreaks are occurring in a wider range of places. And the most vulnerable—children who have received zero vaccines—are being left further behind.

The WHO's message at WHA79 was unambiguous: no country can afford complacency. The Big Catch-Up initiative demonstrated what strong political commitment, financing, and partnership can achieve—countries not only reached children who missed vaccinations during the COVID-19 pandemic but strengthened primary health care systems to ensure no child is left behind. Recovery, however, is not enough. The work now must push deeper: reaching chronically missed populations, countering misinformation, building trust, and fortifying routine programmes so they can withstand inevitable future shocks.

Alongside malaria success, parallel efforts are accelerating to meet other deadly threats. The Tuberculosis Vaccine Accelerator Council met on the sidelines of the assembly to intensify preparations for novel TB vaccines targeting adults and adolescents. Clinical trials are on track to deliver efficacy data by 2028. Even as those trials unfold, countries and partners are engaged in ahead-of-time planning for rollout, financing, equitable access, and community acceptance. TB remains one of the world's deadliest infectious diseases, and new vaccines are positioned as a global priority to shift the epidemic's trajectory.

Across all these efforts—recovering routine programmes, introducing new vaccines, accelerating innovation—one principle anchors the work: equity. Reaching children with vaccines in a timely way means systematically innovating in every community to reach underserved populations. It is, speakers noted, not only one of the highest returns on investment in global health. It is essential to health security and sustainable development. And fundamentally, it is the moral and human thing to do.

The moment has moved from words and commitments into action. What happens next, at the local level across African countries and beyond, will determine whether this renewed pledge becomes the turning point in child survival it promises to be.